描述
Infliximab is a chimeric monoclonal antibody targeting TNF??, widely used in biomedical research to model and treat inflammatory and autoimmune diseases like rheumatoid arthritis, Crohn’s disease, ulcerative colitis, and psoriasis. The Leiting® brand (CMAB008) is China’s first domestically manufactured infliximab biosimilar, produced via CHO cell expression with demonstrated similarity in safety and efficacy.
Provided in 100?mg/vial × 8 vials per box, this injectable formulation is ideal for researchers studying cytokine inhibition, inflammatory cascade modulation, and anti-TNF therapeutic mechanisms. Produced by Taizhou Mabpharm Co., Ltd. and approved under NMPA S20210025, this product also holds rapid GMP recognition for overseas markets .
?? For laboratory research only. Not for clinical, therapeutic, diagnostic, or veterinary use.
Infliximab for Injection Product Specifications
Parameter | Details |
---|---|
Product Name | Infliximab for Injection (Leiting®) |
Generic Name | Infliximab |
CAS Number | 170277?31?3 |
Molecular Type | Chimeric anti-TNF?? monoclonal antibody |
Formulation | Lyophilized powder for IV injection |
Strength | 100?mg per vial |
Package | 8 vials per box |
Approval Number | S20210025 (China NMPA) |
Product Code/Base | 86981463000014 ([barcode pending]; contact for details) |
Manufacturer | Taizhou Mabpharm Co., Ltd. (China) |
Intended Use | Laboratory research only |
Storage Conditions | Store 2–8?°C, protect from light; reconstitute before use |
Infliximab for Injection Mechanism & Research Applications
Infliximab binds and neutralizes TNF??, disrupting inflammatory signaling pathways. Common research uses include:
-
Autoimmune disease modeling (RA, AS, PsA, IBD)
-
Cytokine release and NF??B signaling studies
-
Inflammation, pain, and immune modulation research
-
Preclinical evaluation of biosimilar efficacy and immunogenicity
Infliximab for Injection Side Effects (Observed in Research Models)
-
Elevated infection susceptibility (bacterial, fungal)
-
Infusion-like reactions: chills, fever, hypotension
-
Hematologic changes, transient hepatic enzyme elevation
-
Autoimmune-like effects such as lupus-like syndromes
-
Rare risk of lymphoma or demyelinating disorders with high/chronic dosing
Infliximab for Injection Safety & Handling
-
Use Restriction: Strictly for laboratory research; not for clinical or veterinary use
-
PPE: Use gloves, lab coat, and safety goggles
-
Storage: Keep refrigerated at 2–8?°C; do not freeze
-
Preparation: Reconstitute under aseptic conditions
-
Disposal: Follow institution’s hazardous biological waste protocols
Core Keywords
Infliximab biosimilar China, Leiting infliximab S20210025, 100?mg infliximab research, anti-TNF antibody lab use, Mabpharm infliximab CMAB008, wholesale infliximab vials, TNF?alpha inhibition research agent, lab-grade infliximab injection
Research Use Disclaimer
This product is intended only for laboratory research purposes. It is not approved for clinical, diagnostic, therapeutic, or veterinary use. Non-approved use may lead to regulatory and health risks. Users should follow institutional biosafety and handling protocols rigorously.
评价
目前还没有评价